How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

8,087 results for

Peptic Ulcer Disease

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

8021. The therapeutic efficacy of misoprostol in peptic ulcer disease. (PubMed)

The therapeutic efficacy of misoprostol in peptic ulcer disease. Misoprostol, a synthetic methyl ester analogue of prostaglandin E1 (PGE1) is both a powerful inhibitor of gastric secretion and is able to protect the gastroduodenal mucosa from damage produced by alcohol, aspirin, naproxen and tolmetin. The results of 12 double-blind, randomized, placebo- and cimetidine-controlled trials involving 4000 patients have been reviewed here and show that misoprostol, given in a dosage of 800 micrograms (...) in the treatment of chronic peptic ulcer and could have a beneficial action in duodenal ulcers refractory to treatment with H2-receptor antagonists. It could benefit compromised groups of ulcer patients who are smokers or alcohol users amd certainly has been shown to protect the gastroduodenal mucosa against damage induced by NSAIDs in healthy volunteers and arthritic patients.

1988 Postgraduate medical journal

8022. Successful eradication of Helicobacter pylori prevents relapse of peptic ulcer disease. (PubMed)

Successful eradication of Helicobacter pylori prevents relapse of peptic ulcer disease. The NIH consensus conference in 1994 recommended that all patients with peptic ulcers should be tested and treated for Helicobacter pylori. Recent studies have shown that the eradication of H. pylori is associated with a significant reduction in the relapse rate of peptic ulcers, but there are few reports about long-term outcome.To evaluate the relapse rate of peptic ulcer in the long-term follow-up (...) patients and only 4% of gastric ulcers recurred after successful eradication during follow-up for 5 years. In contrast, in patients with persistent H. pylori infection all DU and 92% of gastric ulcers recurred.Eradication of H. pylori infection changes the natural course of peptic ulcer.

2002 Alimentary pharmacology & therapeutics

8023. Misoprostol in peptic ulcer disease. (PubMed)

Misoprostol in peptic ulcer disease. Misoprostol, a synthetic prostaglandin E1 (PGE1) methyl ester analog has potent antisecretory and cytoprotective effects on the gastric and duodenal mucosa which should make it an effective drug in the treatment of gastric and duodenal ulcer. In two multicenter, randomised, double-blind, controlled studies involving over 900 patients with endoscopically proven benign gastric ulcer and in six similar studies involving over 2000 patients with active duodenal (...) mucosa from the damaging effects of alcohol and non-steroidal anti-inflammatory drugs. This action may prove of value in the treatment of ulcer patients who are inveterate smokers, alcohol users or who are compelled to consume non-steroidal anti-inflammatory drugs for pain relief from rheumatic and allied diseases.

1987 Prostaglandins

8024. A psychosomatic approach to treatment in the irritable bowel syndrome and peptic ulcer disease with aspects of the design of clinical trials. (PubMed)

A psychosomatic approach to treatment in the irritable bowel syndrome and peptic ulcer disease with aspects of the design of clinical trials. To compare the effects of conventional medical treatment with treatment that combines medical treatment and psychotherapy, 101 out-patients with irritable bowel syndrome (IBS) and 103 with peptic ulcer disease (PUD) were randomly allocated to two treatment groups. All patients with PUD received medical treatment with antacids and anticholinergics

1985 Scandinavian journal of gastroenterology. Supplement

8025. Effect of omeprazole, a substituted benzimidazole, on 24-h intragastric acidity in patients with peptic ulcer disease. (PubMed)

Effect of omeprazole, a substituted benzimidazole, on 24-h intragastric acidity in patients with peptic ulcer disease. Intragastric pH was measured during physiological conditions over 24-h periods in patients with peptic ulcer disease. After single oral doses of 20, 40, and 80 mg omeprazole we found a dose-dependent reduction in mean intragastric acidity ranging from 38% to 99%. After treatment for 1 week with omeprazole, 40 mg daily, with or without an initial loading dose of 80 mg

1984 Scandinavian journal of gastroenterology

8026. Fasting blood levels of gastrin, somatostatin, and pancreatic polypeptide in peptic ulcer disease. (PubMed)

Fasting blood levels of gastrin, somatostatin, and pancreatic polypeptide in peptic ulcer disease. Fasting plasma levels of immunoreactive gastrin, somatostatin, and pancreatic polypeptide (PP) were determined in 67 patients with an endoscopically proven duodenal, pyloric, or prepyloric ulcer. Pretreatment gastrin (45.6 +/- 53.6 pmol/l, mean +/- S.D.) and somatostatin (54.5 +/- 27.5 pg/ml) did not differ significantly from those in 22 healthy controls (21.8 +/- 20.2 pmol/l and 64.8 +/- 24.7 pg (...) /ml, respectively). The gastrin and somatostatin levels were not changed by 3 weeks of treatment either with propantheline and antacids or with cimetidine and antacids. The mean PP value before treatment was significantly (p less than 0.01) higher in duodenal ulcer patients (0.76 +/- 0.55 ng/ml) than in healthy subjects of similar age (0.36 +/- 0.26 ng/ml). The increased PP level was not lowered significantly by medical treatment even when this resulted in healing of the ulcer.

1982 Scandinavian journal of gastroenterology

8027. The influence of antirheumatic drugs on the occurrence of peptic ulcers. A controlled study of patients with chronic rheumatic diseases. (PubMed)

The influence of antirheumatic drugs on the occurrence of peptic ulcers. A controlled study of patients with chronic rheumatic diseases. 46 patients who had an ulcer (verified by X-ray pictures) during treatment at the Rheumatism Foundation Hospital were compared with two patient groups of the same size. The first control group consisted of randomly selected patients who had been examined in the same way for the same indications but where the X-ray pictures did not show any ulcer. The subjects (...) in the second control group were of the same age and sex as the ulcer patients; this control group did not undergo any X-ray examination and had no history of ulcer. The study revealed that although most rheumatic patients were women (as in the first control group) there were significantly more men among the ulcer patients. The use of rapidly dissolving acetylsalicylic acid tablets was more common in the ulcer group; correspondingly the slowly absorbed tablets were used significantly more often

1980 Scandinavian journal of rheumatology

8028. Are endoscopic and/or histologic findings in gastroduodenal mucosa a predictor of clinical outcome in peptic ulcer disease? A 1-year follow-up study after initial healing with either cimetidine or medium-dose antacid. (PubMed)

Are endoscopic and/or histologic findings in gastroduodenal mucosa a predictor of clinical outcome in peptic ulcer disease? A 1-year follow-up study after initial healing with either cimetidine or medium-dose antacid. Patients with duodenal ulcer (DU; n = 79) or prepyloric ulcer (PPU; n = 39) received cimetidine, 400 mg twice daily, or Novaluzid, 10 ml four times daily (acid-neutralizing capacity, 340 mmol/day), in a multicentre, randomized, double-blind trial. Ulcer healing was almost (...) identical with the two treatments at 4, 6, and 12 weeks in the DU group. Cimetidine was significantly more effective than antacids in alleviating symptoms in PPU disease, with no significant difference in ulcer healing. In the PPU group the symptomatic improvement was inferior irrespective of treatment, and there was a significantly lower healing rate at 4 weeks (p less than 0.05) than in the DU group. The relapse rate over a 1-year follow-up period with no therapy did not differ between the two

1988 Scandinavian journal of gastroenterology

8029. Randomised study of the influence of non-steroidal anti-inflammatory drugs on the treatment of peptic ulcer in patients with rheumatic disease. (PubMed)

Randomised study of the influence of non-steroidal anti-inflammatory drugs on the treatment of peptic ulcer in patients with rheumatic disease. Sixty-seven patients with rheumatic disease, treated with non-steroidal anti-inflammatory drugs (NSAIDs), entered a controlled trial with a diagnosis of duodenal (n = 51), gastric (n = 14), or gastric and duodenal (n = 2) ulcers. The main objectives of the study were a comparison of ranitidine and sucralfate in ulcer treatment, and to observe (...) the influence of continued NSAID administration during peptic ulcer therapy. Ulcers healed within nine weeks in 52 patients. The mean healing time was similar in 27 patients given ranitidine 150 mg bd (4.9 weeks) and 25 patients given sucralfate 1 g qid (4.6 weeks). In patients with unhealed ulcers after nine weeks of treatment, healing was obtained in seven after further therapy for 3-9 weeks. Of the 30 patients who continued NSAIDs during treatment with either ranitidine or sucralfate, 23 ulcers healed

Full Text available with Trip Pro

1987 Gut

8030. Management of peptic ulcer disease not related to Helicobacter pylori or NSAIDs. (PubMed)

Management of peptic ulcer disease not related to Helicobacter pylori or NSAIDs. Helicobacter pylori (H. pylori) infection is widely accepted as the most important factor in the pathogenesis of duodenal ulcer. However, in parallel with more effective eradication of H. pylori, the prevalence of H. pylori is changing, and H. pylori-negative peptic ulcer disease appears to be increasing. When making a diagnosis of H. pylori-negative peptic ulcer disease, it is essential to avoid misclassification (...) because of inaccurate diagnosis. In addition, secondary causes may need to be excluded with appropriate investigations. In the absence of H. pylori, nonsteroidal anti-inflammatory drug usage is the most common cause of peptic ulcer; surreptitious nonsteroidal anti-inflammatory drug usage is a cause of unexplained ulcer disease in up to 60% of patients. Hypersecretory syndromes such as Zollinger-Ellison syndrome, although rare, need to be excluded. Once all known etiological factors are excluded

2002 American Journal of Gastroenterology

8031. Changing rates of Helicobacter pylori testing and treatment in patients with peptic ulcer disease. (PubMed)

Changing rates of Helicobacter pylori testing and treatment in patients with peptic ulcer disease. The aim of this study was to identify temporal trends in the rate of Helicobacter pylori (H. pylori) testing, prevalence, and treatment among patients with peptic ulcer disease in Olmsted County, MN, from 1984 through 1997.All 3317 Olmsted County residents with a clinical diagnosis of peptic ulcer disease at the Mayo Clinic from 1984 through 1997 were identified. The complete medical records (...) of an age-, sex-, and calendar year-stratified random sample were reviewed (n = 720); 298 patients (41%) had confirmed peptic ulcer disease. Changes in proportions of H. pylori testing, infection, and treatment over time were analyzed by logistic regression.Of the 298 patients with confirmed peptic ulcer disease, 32% were tested for H. pylori; 36% were positive for infection, of whom 66% received antibiotic therapy. The rate of testing for H. pylori increased from 0% in 1984 to 96% in 1997

2002 American Journal of Gastroenterology

8032. Hospitalization and mortality rates from peptic ulcer disease and GI bleeding in the 1990s: relationship to sales of nonsteroidal anti-inflammatory drugs and acid suppression medications. (PubMed)

Hospitalization and mortality rates from peptic ulcer disease and GI bleeding in the 1990s: relationship to sales of nonsteroidal anti-inflammatory drugs and acid suppression medications. Nonsteroidal anti-inflammatory drugs (NSAIDs) can cause peptic ulcer disease and upper GI bleeding. Acid suppression medications effectively treat NSAID-induced ulcers. However, it is unknown what effect the availability of proton pump inhibitors and over-the-counter preparations of NSAIDs and histamine type 2 (...) receptor antagonists have had on population rates of hospitalization and mortality from GI toxicity. This study examines trends in hospitalization and mortality rates from GI toxicity during the 1990s.We performed an analysis of secular trends of hospitalization and mortality rates from peptic ulcer disease, upper GI bleeding, and any GI bleeding using data from the National Hospital Discharge Survey, comparing them with sales of NSAIDs, aspirin, and acid suppression medications from 1992 to 1999.From

2002 American Journal of Gastroenterology

8033. Helicobacter pylori is a risk factor for peptic ulcer disease in cirrhotic patients. A meta-analysis. (PubMed)

Helicobacter pylori is a risk factor for peptic ulcer disease in cirrhotic patients. A meta-analysis. Peptic ulcer disease is highly prevalent in cirrhosis, and ulcer complications are a major cause of morbidity in these patients. Helicobacter pylori infection is considered the chief aetiological factor of ulcer disease. However, in cirrhotic patients the role of H. pylori in the pathogenesis of peptic ulcer remains uncertain.To evaluate the evidence of the pathogenic role of H. pylori (...) infection in peptic ulcer disease in patients with cirrhosis.An extensive MEDLINE search of the literature was performed. Studies reporting the prevalence of H. pylori infection in cirrhotic patients with and without ulcers were selected. Meta-analysis was conducted using RevMan 4.0.3. Pooled odds ratios were calculated for each comparison, using a fixed model analysis.The search identified seven studies with a total of 976 patients with cirrhosis (275 cases with ulcer disease and 701 controls

2002 European journal of gastroenterology & hepatology

8034. Associations of peptic ulcer and gastric cancer with other diseases in US veterans. (PubMed)

Associations of peptic ulcer and gastric cancer with other diseases in US veterans. The purpose of this study was to examine, through the database of the Department of Veterans Affairs, the joint occurrence of different diseases in individual patients.Patients with a diagnosis of gastric cancer, gastric ulcer, or duodenal ulcer were extracted from the 1987 through 1990 computer files. A random sample of patients from each annual file served as a control population. All previous discharges (...) of each case or control patient between 1970 and 1990 were searched for the occurrence of hypertensive diseases or chronic diseases of the joints, lungs, pancreas, and liver. The relative frequencies of such diagnoses in case and control patients were compared by multivariate logistic regression.Gastric ulcer and duodenal ulcer, but not gastric cancer, were significantly associated with chronic diseases of the joints, lungs, pancreas, and liver. None of the three diagnoses showed any significant

Full Text available with Trip Pro

1995 American Journal of Public Health

8035. Why is peptic ulcer now a disease? (PubMed)

Why is peptic ulcer now a disease? 7959215 1994 12 20 2008 11 21 0017-5749 35 10 1994 Oct Gut Gut Why is peptic ulcer now a disease? 1504-5 Spiro H H Yale University School of Medicine, New Haven, Connecticut 06520-8019. eng Journal Article England Gut 2985108R 0017-5749 AIM IM Duodenal Ulcer etiology pathology Helicobacter Infections complications Humans Peptic Ulcer diagnosis etiology Stomach Ulcer etiology pathology Stress, Physiological 1994 10 1 1994 10 1 0 1 1994 10 1 0 0 ppublish 7959215

Full Text available with Trip Pro

1994 Gut

8036. Muscarinic receptors in gastric mucosa are increased in peptic ulcer disease. (PubMed)

Muscarinic receptors in gastric mucosa are increased in peptic ulcer disease. Muscarinic receptors stimulate the secretion of acid pepsinogen and mucous in gastric mucosa. Whether muscarinic receptors are involved in the pathogenesis of benign gastric disease is unknown. Receptor changes in these conditions were therefore sought. An autoradiographic technique was developed to determine quantitatively muscarinic receptors in microtome sections of biopsy specimens obtained during gastroscopy (...) respectively (p < 0.025). These results suggest that muscarinic M3 receptor is overexpressed in duodenal ulcer disease and may play a part in its pathogenesis.

Full Text available with Trip Pro

1995 Gut

8037. Prevalence and incidence of peptic ulcer disease in a Danish County--a prospective cohort study. (PubMed)

Prevalence and incidence of peptic ulcer disease in a Danish County--a prospective cohort study. Peptic ulcer prevalence and five year incidence were assessed in a sex and age stratified population sample of 3608 Danish subjects aged 30-60 years. Statements of peptic ulcer disease obtained from questionnaires were scrutinised by reviewing medical records. Life time ulcer prevalence (95% confidence intervals) was 5.6 (4.9-6.4) per cent. Male to female prevalence ratio was 2.2:1, and duodenal (...) to gastric ulcer prevalence ratio was 3.8:1. Thirty two participants with no previous history of peptic ulceration developed an ulcer within the observation period resulting in a five year ulcer incidence of 11.3 (7.4-15.2) per 1000 persons at risk with no demonstrable sex difference. The prevalence of duodenal ulcer has declined in Denmark whereas gastric ulcer prevalence in men has increased slightly. A decline in male duodenal ulcer incidence has probably contributed to the low male to female ulcer

Full Text available with Trip Pro

1995 Gut

8038. Abundance of surfactant-like particles reflects mucosal integrity in patients with peptic ulcer disease. (PubMed)

Abundance of surfactant-like particles reflects mucosal integrity in patients with peptic ulcer disease. Surfactant-like particles, normal products of the human enterocyte, are released into the lumen and secreted into blood.To assess their role as markers for mucosal functional integrity, this study examined their content in biopsy specimens and serum of patients with duodenal ulcer disease, compared with non-diseased control subjects.Endoscopic biopsy specimens were taken 1-2 cm from areas (...) (SD) than active duodenal ulcer (n = 13, 17 (3.9)) or gastritis/duodenitis patients (n = 4, 9 (2.7)). Three patients examined after healing of duodenal ulcers showed abundant particles (n = 3, 67 (2.2)). Similarly, the 59 kDa band was decreased in serum of patients with active peptic ulcer disease (n = 11, 0.25 (0.04) absorbance units) compared with normal patients (n = 10, 0.40 (0.03)) or healed ulcers (n = 3, 0.62 (0.04)). There was good correlation between morphological mucosal particle

Full Text available with Trip Pro

1996 Gut

8039. The Helicobacter pylori breath test: a surrogate marker for peptic ulcer disease in dyspeptic patients. (PubMed)

The Helicobacter pylori breath test: a surrogate marker for peptic ulcer disease in dyspeptic patients. There is interest in noninvasive H pylori testing as a means of predicting diagnosis and determining management in dyspeptic patients.To assess the value of the 14C urea breath test as a predictor of peptic ulcer disease in patients presenting with dyspepsia.327 consecutive patients referred for investigation of dyspepsia had a 14C urea breath test performed before endoscopy. Patients were (...) not included if they had previously confirmed ulcer disease, previous gastric surgery, or were taking non-steroidal anti-inflammatory drugs.Of the 182 patients with a positive 14C urea breath test, duodenal and/or gastric ulcers were present in 45% and erosive duodenitis in a further 2%. Oesophagitis was present in 12% of the breath test positive patients with two thirds of the oesophagitis patients having co-existent ulcer disease. The prevalence of ulcer disease in the H pylori positive dyspeptic

Full Text available with Trip Pro

1997 Gut

8040. Audit of the outcome of peptic ulcer disease diagnosed 10 to 20 years previously. (PubMed)

Audit of the outcome of peptic ulcer disease diagnosed 10 to 20 years previously. METHODS/AIMS: During 1993-1994 an audit of the outcomes of a consecutive series of peptic ulcer patients, first diagnosed endoscopically between 1972-1983, was carried out. Three hundred and thirty six patients fitting the entry criteria were identified, 46 had died in the interval, and 44 were lost to follow up, leaving 246 available for evaluation. All patients completed questionnaires on their current (...) who had undergone surgical treatment recording this as a continuing problem (44.6% v 36%).There is no evidence provided by this study that, in these patients, their ulcer disease is undergoing spontaneous remission with time.

Full Text available with Trip Pro

1996 Gut

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>